A
Andrea Castro
Researcher at University of California, San Diego
Publications - 19
Citations - 278
Andrea Castro is an academic researcher from University of California, San Diego. The author has contributed to research in topics: Cancer & Immunotherapy. The author has an hindex of 5, co-authored 13 publications receiving 100 citations. Previous affiliations of Andrea Castro include University of California, Los Angeles.
Papers
More filters
Journal ArticleDOI
Strength of immune selection in tumors varies with sex and age
Andrea Castro,Rachel Marty Pyke,Xinlian Zhang,Wesley K. Thompson,Chi-Ping Day,Ludmil B. Alexandrov,Maurizio Zanetti,Hannah Carter +7 more
TL;DR: It is found that tumors in younger and female individuals accumulate more poorly presented driver mutations than those in older and male patients, despite no differences in MHC genotype.
Journal ArticleDOI
MHC-I genotype and tumor mutational burden predict response to immunotherapy.
Aaron M. Goodman,Andrea Castro,Andrea Castro,Rachel Marty Pyke,Ryosuke Okamura,Shumei Kato,Paul Riviere,Garrett M. Frampton,Ethan Sokol,Xinlian Zhang,Edward D. Ball,Hannah Carter,Hannah Carter,Razelle Kurzrock +13 more
TL;DR: Poor presentation of driver mutation neoantigens by MHC-I may explain why some tumors (even with a high TMB) do not respond to ICB.
Journal ArticleDOI
Elevated neoantigen levels in tumors with somatic mutations in the HLA-A, HLA-B, HLA-C and B2M genes.
TL;DR: These findings add to a growing body of evidence that somatic B2M and HLA mutations are a mechanism of immune evasion by demonstrating that such mutations are associated with a higher load of neoantigens that should be presented via MHC-I.
Journal ArticleDOI
Genomic and evolutionary classification of lung cancer in never smokers
Tongwu Zhang,Philippe Joubert,Naser Ansari-Pour,Wei Zhao,Phuc H Hoang,Rachel Lokanga,Aaron L Moye,Jennifer Rosenbaum,Abel Gonzalez-Perez,Francisco Martínez-Jiménez,Andrea Castro,Lucia Anna Muscarella,Paul Hofman,Dario Consonni,Angela Cecilia Pesatori,Michael Kebede,Mengying Li,Bonnie E. Gould Rothberg,Iliana Peneva,Iliana Peneva,Matthew B. Schabath,Maria Luana Poeta,Manuela Costantini,Daniela Hirsch,Kerstin Heselmeyer-Haddad,Amy Hutchinson,Mary E. Olanich,Scott M. Lawrence,Petra Lenz,Máire A. Duggan,Praphulla M S Bhawsar,Jian Sang,Jung Kim,Laura Mendoza,Natalie Saini,Leszek J. Klimczak,S M Ashiqul Islam,Burcak Otlu,Azhar Khandekar,Nathan Cole,Douglas R. Stewart,Jiyeon Choi,Kevin M. Brown,Neil E. Caporaso,Samuel H. Wilson,Yves Pommier,Qing Lan,Nathaniel Rothman,Jonas S Almeida,Hannah Carter,Thomas Ried,Carla F. Kim,Carla F. Kim,Nuria Lopez-Bigas,Montserrat Garcia-Closas,Jianxin Shi,Yohan Bossé,Bin Zhu,Dmitry A. Gordenin,Ludmil B. Alexandrov,Stephen J. Chanock,David C. Wedge,David C. Wedge,Maria Teresa Landi +63 more
TL;DR: In this paper, a high-coverage whole-genome sequencing of 232 lung cancer in never smokers (LCINS) showed three subtypes defined by copy number aberrations.
Journal ArticleDOI
Telomerase and CD4 T Cell Immunity in Cancer.
TL;DR: It is proposed that monitoring CD4 T cell immunity against TERT is a simple and direct way to assess immune surveillance in cancer patients and a new way to predict the response to immune checkpoint inhibitors (ICPi).